» Articles » PMID: 11779920

Inhibition of Glutamate Release Via Recovery of ATP Levels Accounts for a Neuroprotective Effect of Aspirin in Rat Cortical Neurons Exposed to Oxygen-glucose Deprivation

Overview
Journal Stroke
Date 2002 Jan 10
PMID 11779920
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Aspirin is preventive against stroke not only because of its antithrombotic properties but also by other direct effects. The aim of this study was to elucidate its direct neuroprotective effects.

Methods: Viability parameters, glutamate release and uptake, and ATP levels were measured in cultured cortical neurons exposed to oxygen-glucose deprivation (OGD). In addition, ATP levels and oxygen consumption were studied in isolated brain mitochondria or submitochondrial particles.

Results: Aspirin inhibited OGD-induced neuronal damage at concentrations lower (0.3 mmol/L) than those reported to act via inhibition of the transcription factor nuclear factor-kappaB (which are >1 mmol/L), an effect that correlated with the inhibition caused by aspirin on glutamate release. This effect was shared by sodium salicylate but not by indomethacin, thus excluding the involvement of cyclooxygenase. A pharmacological dissection of the components involved indicated that aspirin selectively inhibits the increase in extracellular glutamate concentration that results from reversal of the glutamate transporter, a component of release that is due to ATP depletion. Moreover, aspirin-afforded neuroprotection occurred in parallel with a lesser decrease in ATP levels after OGD. Aspirin elevated ATP levels not only in intact cortical neurons but also in isolated brain mitochondria, an effect concomitant with an increase in NADH-dependent respiration by brain submitochondrial particles.

Conclusions: Taken together, our present findings show a novel mechanism for the neuroprotective effects of aspirin, which takes place at concentrations in the antithrombotic-analgesic range, useful in the management of patients with high risk of ischemic events.

Citing Articles

A Novel 5-Chloro--phenyl-1-indole-2-carboxamide Derivative as Brain-Type Glycogen Phosphorylase Inhibitor: Potential Therapeutic Effect on Cerebral Ischemia.

Huang Y, Li S, Wang Y, Yan Z, Guo Y, Zhang L Molecules. 2022; 27(19).

PMID: 36234871 PMC: 9572471. DOI: 10.3390/molecules27196333.


Macrophage migration inhibitory factor (MIF) acetylation protects neurons from ischemic injury.

Hu J, Ma W, He L, Zhang C, Zhang C, Wang Y Cell Death Dis. 2022; 13(5):466.

PMID: 35585040 PMC: 9117661. DOI: 10.1038/s41419-022-04918-2.


Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium.

Arteaga-Henriquez G, Simon M, Burger B, Weidinger E, Wijkhuijs A, Arolt V Front Psychiatry. 2019; 10:458.

PMID: 31354538 PMC: 6630191. DOI: 10.3389/fpsyt.2019.00458.


Mechanisms Underlying Neuroprotection by the NSAID Mefenamic Acid in an Experimental Model of Stroke.

Khansari P, Halliwell R Front Neurosci. 2019; 13:64.

PMID: 30792624 PMC: 6374636. DOI: 10.3389/fnins.2019.00064.


Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.

Miyamoto T, Stein L, Thomas R, Djukic B, Taneja P, Knox J Mol Neurodegener. 2017; 12(1):41.

PMID: 28526038 PMC: 5438564. DOI: 10.1186/s13024-017-0176-x.